In retrospect, Pfizer's move to buy another major pharmaceutical company was inevitable. Like its peers, Pfizer has been energetically restructuring itself in recent times, from its salesforces to its R&D, but the fruits of these reforms cannot come quickly enough.
When Lipitor's US patent expires in 2011, it is set to lose most of its current $12 billion annual revenue in the space of just a few years. Meanwhile, other patent expiries and the relative failure of products like smoking cessation drug Champix/Chantix means there is nothing in the company's portfolio to replace it.
Pfizer's acquisitive approach to growth has set the pace for the industry over the last decade, and it is obvious that at least some of its peers could now follow its latest example.
Who? Go here.
No comments:
Post a Comment